CONTENTS VOL. 20, 2002

Volume 20, No. 1

Preclinical studies

Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues – J.A. Sakoff, S.P. Ackland, M.L. Baldwin, M.A. Keane, A. McCluskey 1–11

Preclinical efficacy evaluations of XK-469: Dose schedule, route and cross-resistance behavior in tumor bearing mice – L. Polin, K. White, J. Kushner, J. Paluch, C. Simpson, S. Pugh, M.K. Edelstein, S. Hazeldine, J. Fontana, P. LoRusso, J.P. Horwitz, T.H. Corbett 13–22

Lack of *in vitro – in vivo* correlation of a novel investigational anticancer agent, SH 30 – S. Poondru, R.E. Parchment, V. Purohit, P. LoRusso, J.P. Horwitz, S.T. Hazeldine, L. Polin, T. Corbett, B.R. Jasti 23–33

Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate – O.V. Leontieva, M.N. Preobrazhenskaya, R.J. Bernacki 35–48

Review

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome – Recall following different chemotherapy agents – Y. Fung Hui, F.J. Giles, J.E. Cortes 49–53

Phase I study

Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies – S. Jones, J. Hainsworth, H.A. Burris, III, D. Thompson, E. Raefsky, V. Johnson, S. Calvert, C. Bulanhagui, D. Lebwohl, F.A. Greco 55–61

Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU) – P.M. LoRusso, S. Prakash, A. Wozniak, L. Flaherty, M. Zalupski, A. Shields, H. Sands, R. Parchment, B. Jasti 63–71

Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer – E. Esteban, J. Fra, N. Corral, M. Valle, J. Carrasco, M. Sala, J. Puerta, E. Estrada, I. Palacio, J.M. Vieitez, J.M. Buesa, A.J. Lacave 73–82

Phase II studies

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies – J.H.M. Schellens, B. Heinrich, M. Lehnert, M.E. Gore, S.B. Kaye, P. Dombernowsky, R. Paridaens, A.T. van Oosterom, J. Verweij, W.J. Loos, H. Calvert, N. Pavlidis, H. Cortes-Funes, J. Wanders, M. Roelvink, C. Sessa, K. Selinger, P.S. Wissel, T. Gamucci, A.R. Hanauske 83–93

Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus – E.I. Heath, S. Urba, J. Marshall, S. Piantadosi, A.A. Forastiere 95–99

Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in renal cell cancer – K.M. Skubitz 101–103

A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy – Southwest Oncology Group study – R.P. Whitehead, J.M. Unger, L.E. Flaherty, E.H. Kraut, G.M. Mills, C.E. Klein, R.A. Chapman, G.C. Doolittle, N. Hammond, V.K. Sondak 105–111

Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group study – S.A. Taylor, C. Rankin, J.J. Townsend, J.B. Craig, R.B. Vance, D.L. Solank, T.D. Brown, K. Jaeckle 113–115

The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study – J.K. Weick, J.J. Crowley, M.A. Hussein, D.F. Moore, B. Barlogie 117–121

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck – D.G. Pfister, J. McCaffrey, A.J. Zahalsky, G.K. Schwartz, E. Lis, W. Gerald, A. Huvos, J. Shah, D. Kraus, A. Shaha, B. Singh, S. Wolden, M. Zelefsky, I. Palgi 123–127

Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study – G.T. Budd, C. Rankin, L.F. Hutchins, L. Wong, P.J. Petruska, K. Antman 129–132

Short communication

Raltitrexed (Tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study – N. Tsavaris, C. Kosmas, M. Vadiaka, A. Kontos, M. Fotia, A. Angelopoulou, N. Vrizidis, M. Soulla, S. Sougioultzis, Ch. Koufos 133–136

Volume 20, No. 2

Preface: New therapeutic strategies for prostate cancer: reasons for optimism and reflection – A.W. Tolcher 143–144

Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer – M.E. Gleave, T. Zellweger, K. Chi, H. Miyake, S. Kiyama, L. July, S. Leung 145–158

Signaling inhibitors in the treatment of prostate cancer – G.R. Hudes 159–172

Endothelin-1 as a target for therapeutic intervention in prostate cancer – E.S. Kopetz, J.B. Nelson, M.A. Carducci 173–182

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer – W.D. Figg, E.A. Kruger, D.K. Price, S.Kim, W.D. Dahut 183–194

Peroxisome proliferator-activated receptor gamma (PPARγ) as a novel target for prostate cancer – M.R. Smith, P.W. Kantoff 195–200

New trial designs to assess antitumor and antiproliferative agents in prostate cancer – W. Stadler 201–208

Suramin's development: what did we learn? – M. Kaur, E. Reed, O. Sartor, W. Dahut, W.D. Figg 209–219

Announcement 221–222

Volume 20, No. 3

Preclinical studies

Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas *in vitro* – J. Milošević, S. Kanazir, L. Medić-Mijačević, V. Pejanović, Z. Stokić, G. Konjević, L. Rakić, S. Ruždijić 229–240

Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts – B.A. Teicher, K. Menon, E. Alvarez, Chuan Shih, M.M. Faul 241–251

A novel high-through-put assay for screening of pro-apoptotic drugs – M. Hägg, K. Bivén, T. Ueno, L. Rydlander, P. Björklund, K.G. Wiman, M. Shoshan, S. Linder 253–259

Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642) – D. Hao, J.D. Rizzo, S. Stringer, R.V. Moore, J. Marty, D.L. Dexter, G.L. Mangold, J.B. Camden, D.D. Von Hoff, S.D. Weitman 261–270

Enhanced antitumor activity of irofulven in combination with antimitotic agents – M.J. Kelner, T.C. McMorris, R.J. Rojas, N.A. Trani, T.R. Velasco, L.A. Estes, P. Suthipinijtham 271–279

5,6-Dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy – S. Zhou, P. Kestell, B.C. Baguley, J.W. Paxton 281–295

Phase I studies

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer – A.A. Adjei, J.M. Reid, C. Erlichman, J.A. Sloan, H.C. Pitot, S.R. Alberts, R.M. Goldberg, L.J. Hanson, S. Ruben, S.A. Boerner, P. Atherton, M.M. Ames, S.H. Kaufmann 297–304

A Phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma – F. Perez-Zincer, T. Olencki, G.T. Budd, D. Peereboom, P. Elson, R.M. Bukowski 305–310

A report on serious pulmonary toxicity associated with gemcitabine-based therapy – D.F. Roychowdhury, C.A. Cassidy, P. Peterson, M. Arning 311–315

Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer – E. Esteban, J. Fra, M. Sala, J. Carrasco, N. Corral, J.M. Vieitez, E. Estrada, I. Palacio, J.M. Buesa, A.J. Lacave 317–326

Phase II studies

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma – J. Vuky, R. Yu, L. Schwartz, R.J. Motzer 327–330

A phase II study of Caelyx™ (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation – R. McMenemin, G. Macdonald, L. Moffat, D. Bissett 331–337

Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung – A Kansas Cancer Institute and Thompson Cancer Survival Center Study – M. Bastasch, T.J. Panella, S.L. Kretzschmer, D. Graham, M. Mayo, S. Williamson 339–342

A Phase I study of SPI-077 (Stealth® liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer – D.I. Rosenthal, S.S. Yom, L. Liu, M. Machtay, K. Algazy, R.S. Weber, G.S. Weinstein, A.A. Chalian, L.K. Miller, K. Rockwell, Jr, M. Tonda, E. Schnipper, D. Hershock 343–349

Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangiocarcinomas – R. Kuhn, A. Hribaschek, K. Eichelmann, S. Rudolph, J. Fahlke, K. Ridwelski 351–356

A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma – A.S. Pierson, P. Gibbs, J. Richards, P. Russ, S.G. Eckhardt, R. Gonzalez 357–362

Volume 20, No. 4

Phase I studies

Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study – C.A. Presant, J. Jacobson, W. Wolf, V. Waluch, I.C. Weitz, J.S. Macdonald 369–376

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy – S. Morgan-Meadows, J.P. Thomas, D. Mulkerin, J.D. Berlin, H. Bailey, K. Binger, J. Volkman, D. Alberti, C. Feierabend, R. Marrocha, R.Z. Arzoomanian, G. Wilding 377–382

Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study – A.A. Garcia, M.A. Bookman, L. Rodriguez-Rodriguez, D.G. Mutch, K.Y. Look 383–387

A phase II study of thalidomide in advanced metastatic renal cell carcinoma – D.A. Minor, D. Monroe, L.A. Damico, G. Meng, U. Suryadevara, L. Elias 389–393

Review

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse – M.S. Berger, L.H. Leopold, J.A. Dowell, J.M. Korth-Bradley, M.L. Sherman 395–406

Phase II studies

A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study – R.G. Tozer, S. Burdette-Radoux, K. Berlanger, M.L. Davis, R.C. Lohmann, J.R. Rusthoven, N. Wainman, B. Zee, L. Seymour 407–412

Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer – R.J. Amato, C. Perez, L. Pagliaro 413–417

Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer – C.G. Leichman, K. Chansky, J.S. Macdonald, M.A. Doukas, G.T. Budd, J.K. Giguere, J.L. Abbruzzese 419–424

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): A phase II trial of the Eastern Cooperative Oncology Group – B.J. Roth, J. Manola, R. Dreicer, D. Graham, G. Wilding 425–429

Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group – I. Quirt, A. Bodurtha, R. Lohmann, J. Rusthoven, K. Belanger, V. Young, N. Wainman, W. Steward, E. Eisenhauer 431–437

Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer – M. Van Kooten, M. Rosenberg, M. Orlando, J. Morero, M. Vilanova, O. Rojas, H. Vicente, C. Bagnes, C. Silva, R.D. Chacón 439–446

Announcement 447

Contents Volume 20, 2001 449–452

Author Index 453–454

Instructions for authors 455–459